Safety and efficacy of durvalumab with R-CHOP or R-2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Nowakowski, GS; Willenbacher, W; Greil, R; Larsen, TS; Patel, K; Jager, U; Manges, RF; Trumper, L; Everaus, H; Kalakonda, N; Brown, P; Jorgensen, JM; Cunningham, D; Dell'Aringa, J; Fox, B; Rubio, ND; Kilavuz, N; Casadebaig, ML; Manzke, O; Munoz, J

Nowakowski, GS (通讯作者)，Mayo Clin, Div Hematol, 200 1st St SW, Rochester, MN 55902 USA.

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022; 115 (2): 222

Abstract

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, pred......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索